Clinical Trial Update: Efficacy of NF-kB Inhibition for Reducing Symptoms During Maintenance Therapy in Multiple Myeloma Patients [Phase 2]

View source ↗

Summary

The Phase 2 trial NCT01269203 investigating an NF-kB inhibitor to reduce symptoms during maintenance therapy in multiple myeloma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Multiple Myeloma | Phase 2 | Status: WITHDRAWN